Pharmexa A/S of Denmark has decided to change its therapeutic focus from vaccines to human antibodies and will accomplish this by merging with the privately-owned Norwegian antibody research company, Affitech AS. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
